Navigation Links
Intradigm Closes Final Tranche of $21.4 Million Series B Financing
Date:1/7/2009

PALO ALTO, Calif., Jan. 7 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that the company has closed the final tranche of its Series B financing. Astellas Venture Management led the $2.9 million tranche, with existing investor, Lilly Ventures, also participating. The addition of these funds brings the total Series B financing to $21.4 million. Intradigm will use Series B funds to advance its RNAi therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its proprietary delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.

"Intradigm's uniquely comprehensive approach to developing RNAi therapeutics, which encompasses safe and effective delivery, proprietary siRNA sequences and novel structural features for RNAi molecules, makes the company an attractive investment in the rapidly growing RNAi space," said Shinja Yano, Ph.D., president and chief executive officer, Astellas Venture Management LLC. "We are excited to join Intradigm's group of investors and look forward to contributing to the company's future success in recognizing the substantial promise of RNAi as a therapeutic class."

Intradigm today also provided an update on recent corporate developments, announcing that Mohammad Azab, M.D., has resigned his position as chief executive officer but will retain his position on Intradigm's board of directors. Dr. Azab will be succeeded as chief executive officer by Philip Haworth, Ph.D., who previously served as the company's vice president of business development.

"The board would like to thank Dr. Azab for his valuable contributions to building the company and successfully raising the recent Series B financing. We are delighted that he will continue his strategic role on Intradigm's board," said J
'/>"/>

SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industryā€¯ is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Will Help Drive Company,s Commercialization of,Eligen(R) Technology, ... (Nasdaq: EMIS ) has announced that Nicholas ... of Strategy and Development. In this,capacity, Mr. Hart ... aspects of the company,s Eligen(R) technology, including,Eligen(R) B12., ...
... & Co., Inc. Biomarker,Imaging Program -, - ... Broadens Applications in Key Areas of Disease Research ... VisEn Medical, Inc., a leader,in fluorescence in ... commercial launch of its IntegriSenseTM fluorescence in vivo,imaging ...
... Detect Toxicity -, HOPKINTON, Mass., Aug. 19 ... that it has received a $1.1,million task order under ... This task order was issued,pursuant to a contract that ... the ToxCast program. The contract provides for up to ...
Cached Biology Technology:Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development 2Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development 3VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent 2Caliper Life Sciences Receives $1.1 Million Task Order from the EPA's ToxCast(TM) Screening Program 2Caliper Life Sciences Receives $1.1 Million Task Order from the EPA's ToxCast(TM) Screening Program 3Caliper Life Sciences Receives $1.1 Million Task Order from the EPA's ToxCast(TM) Screening Program 4
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... Eos: Long-Term Ecological Research and Network-Level Science, , Imagine ... wide range of ecosystems was responding to global changes ... powerful if it coupled multiple decades of information about ... and models from dozens of different ecosystem types. ... Long-Term Ecological Research (LTER) Network, which will soon celebrate ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... of storm surge and sea-level rise have become ... weeks following Hurricane Sandy,s catastrophic landfall along the ... Brubaker of the Virginia Institute of Marine Science ... sea-level variabilitythe "intra-seasonal" changes that occupy the middle ...
... a glacier,s past, potentially allowing them to more accurately assess how ... been published today, 27 November, in IOP Publishing,s journal Environmental ... can be extended way past the instrumental record. Much ... is, measuring the width of rings on the stem of a ...
... 26, 2012 Webcast AdvisoryWhat:Announcement of a state-of-the-art pediatric ... team racing to unlock genomic codes and develop ... biomedical breakthroughs that will give new hope to ... Hospital, in collaboration with Translational Genomics Research Institute ...
Cached Biology News:Researcher studies 'middle ground' of sea-level change 2Researcher studies 'middle ground' of sea-level change 3Researcher studies 'middle ground' of sea-level change 4Researcher studies 'middle ground' of sea-level change 5Shrubs lend an insight into a glacier's past 2
...
... Clone/PAD: ZMD.358. Immunogen: Synthetic ... region of human mouse and ... with human and mouse LRP5 ... (positive controls: mouse LRP5-pSEC-tag-transfected 293T ...
...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: